Background: Hepatitis C virus (HCV) is a leading cause of hepatocellular carcinoma (HCC).
In the United States, this form of cancer occurs in approximately 15 000 persons annually. A …

More than two decades of intense research has provided a detailed understanding of
hepatitis C virus (HCV), which chronically infects 2% of the world's population. This effort has …

Background The stability and propagation of hepatitis C virus (HCV) is dependent on a
functional interaction between the HCV genome and liver-expressed microRNA-122 (miR …

Background In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in
previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 …

Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …

Current and Future Therapies for Hepatitis C Virus Infection | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …

The availability of the first molecular clone of the hepatitis C virus (HCV) genome allowed
the identification and biochemical characterization of two viral enzymes that are targets for …

Great progress has been made over the past years in elucidating the structure and function
of the hepatitis C virus (HCV) proteins, most of which are now actively being pursued as …

Background & Aims In phase III trials, the safety profile of triple therapy (pegylated
interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment …

We are entering an important new chapter in the story of hepatitis C virus (HCV) infection.
There are clear challenges and opportunities. On the one hand, new HCV infections are still …